Business Context and Reporting Period
Aimei Health Technology Co., Ltd. (AFJK) filed this Form 8-K on November 6, 2025, to report the results of an Extraordinary General Meeting (EGM) held on the same date. The meeting addressed a proposed business combination with United Hydrogen Global Inc. ("Pubco"). The company is an emerging growth company incorporated in the Cayman Islands.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to capital structure and shareholder actions:
- Outstanding Shares (Record Date): 6,121,733 ordinary shares as of September 26, 2025.
- Shares Tendered for Redemption: 3,950,411 public shares were tendered for redemption as of the reporting date.
- Proposed New Issuance: Approximately 157,568,133 new ordinary shares are proposed to be issued upon closing of the business combination.
Material Changes and Voting Results
Shareholders voted on four proposals. The Business Combination and Merger proposals passed, while the Share Issuance and Adjournment proposals also received approval, though with lower support.
| Proposal | Votes For | Votes Against | Percentage For | Result |
|---|---|---|---|---|
| 1. Business Combination Agreement | 3,832,573 | 1,580,804 | 70.80% | Approved |
| 2. Merger Proposal | 3,832,573 | 1,580,804 | 70.80% | Approved |
| 3. Share Issuance Proposal | 3,639,303 | 1,774,074 | 67.23% | Approved |
| 4. Adjournment Proposal | 3,639,303 | 1,774,074 | 67.23% | Approved |
Outlook, Risks, and Contingencies
Transaction Status: The company expects to complete the business combination as soon as practicable, subject to regulatory approvals and other conditions. The current termination date for the transaction is December 6, 2025.
Extension Contingency: The company has filed a proxy statement for a potential "Extension EGM" on November 10, 2025. If the business combination is not consummated by December 6, 2025, this meeting will seek shareholder approval to extend the deadline. If the combination closes before the Extension EGM, the extension meeting will be cancelled.
Redemption Mechanics: Redemption of the 3,950,411 tendered shares will occur upon the closing of the business combination. If the extension is approved and shareholders elect to redeem again at the Extension EGM, redemptions will be effected at that time.
Risks: The filing includes standard forward-looking statement disclaimers, noting uncertainties regarding the ability to complete the initial business combination and other risks detailed in SEC filings.
Investor Verification Checklist
- Verify the final count of shares tendered for redemption versus the total outstanding to assess the impact on the company's cash reserves and post-merger capitalization.
- Confirm whether the Extension EGM scheduled for November 10, 2025, is cancelled or proceeds, indicating the status of the December 6, 2025, deadline.
- Review the definitive proxy statement for details on the 157,568,133 proposed new share issuance and its dilution effect.
- Monitor regulatory approval status, which is a stated condition for closing the transaction.